Skip to Main Content

After months of horse-trading, hand-wringing, and heated debate, the $74 billion merger of Bristol-Myers Squibb and Celgene was finally approved by shareholders on Friday. “We’re very excited about the new company,” Giovanni Caforio, Bristol’s chairman and CEO, said at the meeting.

Now what?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • CELG lost their spectacular leadership, when appointing Mark Alles
    as CEO. They by passed Jackie Fouse’ , COO , President and most
    important entrepreneurial , Sell Side favorite person in management,
    so they could appoint a bright guy , Mark Alles who didn’t have CEO ability. The very costly Mongersen deal for a PH I/II Italian asset with no proof of concept . Alles as CEO obviously didn’t read the electronic NDA filing and missed the absence of Pre Clinical Data on Ozanimod as well as its Metabolite. This is the most costly blunder in Biotech History, costing the Company 70% of its market cap and its independent status. Now the BMY rescue. I believe Giovanni Caforio (CEO) and Tom Lynch (CSO) of BMY will allow for the creation of an Oncology Giant. I would own the CVR, as the chance of it paying off is high, IMHO. First time in my 25 years in the sector that such a horrendous blunder created a Giant Merger. My $.02 worth.

    • Actually both Celgene and Brystol Myers Squibb shareholders approved the merger today. The former did so with around 70% of votes in favor, the latter with around 75%. Its a done deal.

Comments are closed.